CN104491871A - 一种基于聚谷氨酸和胱胺的pH与还原敏感性的纳米微凝胶 - Google Patents
一种基于聚谷氨酸和胱胺的pH与还原敏感性的纳米微凝胶 Download PDFInfo
- Publication number
- CN104491871A CN104491871A CN201410724506.7A CN201410724506A CN104491871A CN 104491871 A CN104491871 A CN 104491871A CN 201410724506 A CN201410724506 A CN 201410724506A CN 104491871 A CN104491871 A CN 104491871A
- Authority
- CN
- China
- Prior art keywords
- solution
- microgel
- polyglutamic acid
- concentration
- nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010020346 Polyglutamic Acid Proteins 0.000 title claims abstract description 54
- 229920002643 polyglutamic acid Polymers 0.000 title claims abstract description 54
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 229940099500 cystamine Drugs 0.000 title claims abstract description 33
- 230000009467 reduction Effects 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 29
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000002105 nanoparticle Substances 0.000 claims abstract description 10
- 239000002245 particle Substances 0.000 claims abstract description 10
- 238000004132 cross linking Methods 0.000 claims abstract description 9
- 239000003054 catalyst Substances 0.000 claims abstract description 5
- 230000009881 electrostatic interaction Effects 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 32
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 21
- 229960003180 glutathione Drugs 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 235000003969 glutathione Nutrition 0.000 claims description 11
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 claims description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
- 229910052708 sodium Inorganic materials 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 8
- 239000000385 dialysis solution Substances 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 claims description 4
- 229930195573 Amycin Natural products 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 3
- 229960002918 doxorubicin hydrochloride Drugs 0.000 claims description 3
- 238000002474 experimental method Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 3
- 229910052748 manganese Inorganic materials 0.000 claims description 3
- 239000011572 manganese Substances 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910001410 inorganic ion Inorganic materials 0.000 claims description 2
- 238000007689 inspection Methods 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 12
- 206010028980 Neoplasm Diseases 0.000 abstract description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract description 6
- 201000011510 cancer Diseases 0.000 abstract description 6
- 239000002253 acid Substances 0.000 abstract description 5
- 239000003960 organic solvent Substances 0.000 abstract description 4
- -1 carboxylate anions Chemical class 0.000 abstract description 3
- 229960004679 doxorubicin Drugs 0.000 abstract description 3
- 108010024636 Glutathione Proteins 0.000 abstract description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 239000003431 cross linking reagent Substances 0.000 abstract description 2
- 238000007112 amidation reaction Methods 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 19
- 230000000694 effects Effects 0.000 description 14
- 230000008859 change Effects 0.000 description 7
- 239000003638 chemical reducing agent Substances 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012673 precipitation polymerization Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410724506.7A CN104491871B (zh) | 2014-12-02 | 2014-12-02 | 一种基于聚谷氨酸和胱胺的pH与还原敏感性的纳米微凝胶 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410724506.7A CN104491871B (zh) | 2014-12-02 | 2014-12-02 | 一种基于聚谷氨酸和胱胺的pH与还原敏感性的纳米微凝胶 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104491871A true CN104491871A (zh) | 2015-04-08 |
CN104491871B CN104491871B (zh) | 2017-03-29 |
Family
ID=52933383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410724506.7A Active CN104491871B (zh) | 2014-12-02 | 2014-12-02 | 一种基于聚谷氨酸和胱胺的pH与还原敏感性的纳米微凝胶 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104491871B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104817660A (zh) * | 2015-05-13 | 2015-08-05 | 江南大学 | 一种改性羧甲基壳聚糖纳米凝胶的制备 |
CN105395483A (zh) * | 2015-12-21 | 2016-03-16 | 江南大学 | 一种可还原降解超支化聚合物纳米胶束及其制备方法 |
CN105434357A (zh) * | 2015-12-21 | 2016-03-30 | 江南大学 | 一种两性离子纳米颗粒的制备 |
CN107098988A (zh) * | 2017-05-03 | 2017-08-29 | 江南大学 | 一种黄原胶纳米微凝胶的制备方法 |
CN110859826A (zh) * | 2019-12-09 | 2020-03-06 | 深圳先进技术研究院 | 一种脑肿瘤靶向的仿生载药纳米颗粒及其制备方法和用途 |
CN111388447A (zh) * | 2018-12-27 | 2020-07-10 | 深圳先进技术研究院 | 阿霉素纳米颗粒及其制备方法和应用、声动力联合化学治疗肿瘤的药物 |
CN111410757A (zh) * | 2020-03-31 | 2020-07-14 | 江南大学 | 一种可降解及环境响应性复合物微凝胶的制备方法 |
US10933028B2 (en) | 2018-05-08 | 2021-03-02 | Jiangnan University | Method of preparing pH/reduction responsive polyamino acid zwitterionic nanoparticles |
CN112547019A (zh) * | 2020-12-02 | 2021-03-26 | 上海工程技术大学 | 一种拆分外消旋克唑替尼的方法 |
CN113041359A (zh) * | 2021-03-26 | 2021-06-29 | 湖南师范大学 | 一种谷胱甘肽响应性抗骨肉瘤前药纳米粒子及其制备方法和用途 |
-
2014
- 2014-12-02 CN CN201410724506.7A patent/CN104491871B/zh active Active
Non-Patent Citations (8)
Title |
---|
BAE, HEE HO ET AL: ""Bio-derived poly(γ-glutamic acid) nanogels as controlled anticancer drug delivery carriers"", 《J. MICROBIOL. BIOTECHNOL》 * |
BHAVIK MANOCHA: ""Controlled Release of Doxorubicin from Doxorubicin/γ-Polyglutamic Acid Ionic Complex"", 《JOURNAL OF NANOMATERIALS》 * |
MICHIYA MATSUSAKI ET AL: "The construction of 3D-engineered tissues composed of cells and extracellular matrices by hydrogel template approach", 《BIOMATERIALS》 * |
MINGQIANG LI ET AL: "Nanoscaled Poly(L-glutamic acid)/Doxorubicin-Amphiphile Complex as pH-responsive Drug Delivery System for Effective Treatment of Nonsmall Cell Lung Cancer", 《APPLIED MATERIALS & INTERFACES》 * |
庄华红等: "r-聚谷氨酸水凝胶的制备、性能及其应用", 《应用化学》 * |
曾戎: "《多糖基高分子-药物轭合物的设计、合成、表征和评价》", 31 May 2011 * |
汤继辉等: "聚氨基酸作为药物载体的研究进展", 《中国药科大学学报》 * |
薛巍: "《生物医用水凝胶》", 31 December 2012 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104817660A (zh) * | 2015-05-13 | 2015-08-05 | 江南大学 | 一种改性羧甲基壳聚糖纳米凝胶的制备 |
CN104817660B (zh) * | 2015-05-13 | 2017-05-10 | 江南大学 | 一种改性羧甲基壳聚糖纳米凝胶的制备 |
CN105395483A (zh) * | 2015-12-21 | 2016-03-16 | 江南大学 | 一种可还原降解超支化聚合物纳米胶束及其制备方法 |
CN105434357A (zh) * | 2015-12-21 | 2016-03-30 | 江南大学 | 一种两性离子纳米颗粒的制备 |
CN105395483B (zh) * | 2015-12-21 | 2018-09-28 | 江南大学 | 一种可还原降解超支化聚合物纳米胶束及其制备方法 |
CN107098988A (zh) * | 2017-05-03 | 2017-08-29 | 江南大学 | 一种黄原胶纳米微凝胶的制备方法 |
US10933028B2 (en) | 2018-05-08 | 2021-03-02 | Jiangnan University | Method of preparing pH/reduction responsive polyamino acid zwitterionic nanoparticles |
CN111388447A (zh) * | 2018-12-27 | 2020-07-10 | 深圳先进技术研究院 | 阿霉素纳米颗粒及其制备方法和应用、声动力联合化学治疗肿瘤的药物 |
CN110859826A (zh) * | 2019-12-09 | 2020-03-06 | 深圳先进技术研究院 | 一种脑肿瘤靶向的仿生载药纳米颗粒及其制备方法和用途 |
CN110859826B (zh) * | 2019-12-09 | 2022-04-05 | 深圳先进技术研究院 | 一种脑肿瘤靶向的仿生载药纳米颗粒及其制备方法和用途 |
CN111410757A (zh) * | 2020-03-31 | 2020-07-14 | 江南大学 | 一种可降解及环境响应性复合物微凝胶的制备方法 |
US11191728B2 (en) | 2020-03-31 | 2021-12-07 | Jiangnan University | Method of preparing degradable and environment responsive composite microgels |
CN112547019A (zh) * | 2020-12-02 | 2021-03-26 | 上海工程技术大学 | 一种拆分外消旋克唑替尼的方法 |
CN113041359A (zh) * | 2021-03-26 | 2021-06-29 | 湖南师范大学 | 一种谷胱甘肽响应性抗骨肉瘤前药纳米粒子及其制备方法和用途 |
CN113041359B (zh) * | 2021-03-26 | 2022-05-20 | 湖南师范大学 | 一种谷胱甘肽响应性抗骨肉瘤前药纳米粒子及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN104491871B (zh) | 2017-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104491871A (zh) | 一种基于聚谷氨酸和胱胺的pH与还原敏感性的纳米微凝胶 | |
Wu et al. | Biocompatible and biodegradable zeolitic imidazolate framework/polydopamine nanocarriers for dual stimulus triggered tumor thermo-chemotherapy | |
CN106139144B (zh) | 一种具有协同抗肿瘤特性的透明质酸修饰的金-碳纳米球及其制备方法与应用 | |
Chang et al. | Self-healable hydrogel on tumor cell as drug delivery system for localized and effective therapy | |
Zhao et al. | Intelligent and spatiotemporal drug release based on multifunctional nanoparticle-integrated dissolving microneedle system for synergetic chemo-photothermal therapy to eradicate melanoma | |
Ding et al. | Tumor targeted nanostructured lipid carrier co-delivering paclitaxel and indocyanine green for laser triggered synergetic therapy of cancer | |
CN108553458B (zh) | 一种抗肿瘤纳米药物 | |
CN104758931B (zh) | 一种基于功能化氧化石墨烯温敏水凝胶的制备方法及其应用 | |
CN107595809B (zh) | 一种玉米醇溶蛋白纳米包埋缓释填充物及其制备方法 | |
CN105056233A (zh) | 具有近红外光热和体内荧光成像特性的多功能介孔二氧化硅纳米粒及其制备方法和应用 | |
CN105713046B (zh) | 一种铂类抗肿瘤前体药物,其纳米水凝胶药物及其制备方法 | |
CN104817660B (zh) | 一种改性羧甲基壳聚糖纳米凝胶的制备 | |
Qian et al. | Injectable self-healing polysaccharide hydrogel loading CuS and pH-responsive DOX@ ZIF-8 nanoparticles for synergistic photothermal-photodynamic-chemo therapy of cancer | |
Gao et al. | AuNRs@ MIL-101-based stimuli-responsive nanoplatform with supramolecular gates for image-guided chemo-photothermal therapy | |
CN108785275A (zh) | 一种包埋有抗癌药物的靶向-光热聚合物微粒的制备方法 | |
CN105535991B (zh) | 用于治疗肿瘤的两亲性碱基缀合物纳米颗粒及其制备方法 | |
CN106606778B (zh) | 含磷酸胆碱聚合物包覆的核壳式磁性复合粒子及其制备方法 | |
CN110302395B (zh) | 一种可促肿瘤凝血和酶/pH双重响应性释药的纳米粒子及其制备方法与应用 | |
Sobhani et al. | Graft hyper-branched dendrimer onto WS2 nanosheets modified Poly (N-Vinylcaprolactam) as a thermosensitive nanocarrier for Pioglitazone delivery using near-infrared radiation | |
Far et al. | Co-delivery of doxorubicin/sorafenib by DNA-decorated green ZIF-67-based nanocarriers for chemotherapy and hepatocellular carcinoma treatment | |
Liu et al. | Polypyrrole coated PLGA core–shell nanoparticles for drug delivery and photothermal therapy | |
Ma et al. | A pH-targeted and NIR-responsive NaCl-nanocarrier for photothermal therapy and ion-interference therapy | |
CN105056244A (zh) | 一种介孔门控型的Fe2+供体与Fe2+依赖性抗肿瘤药物共转运体系及其制备方法与应用 | |
CN103624268A (zh) | 新型抗癌荧光含糖银纳米团簇的制备方法 | |
Tian et al. | Porphyrin-based porous organic polymer coated ZIF-8 nanoparticles as tumor targeted photosensitizer for combination cancer photodynamic/photothermal therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201127 Address after: 226000 Jiangsu city of Nantong province Gangzha Industrial Zone happiness (Wen Jun Cun group four) Patentee after: NANTONG HUIYUAN PLASTIC Co.,Ltd. Address before: No. 1800 road 214122 Jiangsu Lihu Binhu District City of Wuxi Province Patentee before: Jiangnan University |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A nano gel based on pH and reduction sensitivity of polyglutamic acid and cystamine Effective date of registration: 20230423 Granted publication date: 20170329 Pledgee: Bank of China Limited by Share Ltd. Nantong branch Pledgor: NANTONG HUIYUAN PLASTIC Co.,Ltd. Registration number: Y2023980038973 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20170329 Pledgee: Bank of China Limited by Share Ltd. Nantong branch Pledgor: NANTONG HUIYUAN PLASTIC Co.,Ltd. Registration number: Y2023980038973 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A nano gel based on pH and reduction sensitivity of polyglutamic acid and cystamine Granted publication date: 20170329 Pledgee: Bank of China Limited by Share Ltd. Nantong branch Pledgor: NANTONG HUIYUAN PLASTIC Co.,Ltd. Registration number: Y2024980016210 |